Intermediate-term performance of CryoLife cryopreserved heart valve allografts

  title={Intermediate-term performance of CryoLife cryopreserved heart valve allografts},
  author={David Fronk and Scott B. Capps and Robert T. Mcnally},
CryoLife, Inc., a tissue processing laboratory, specializes in ultra-low temperature preservation of human tissues for transplant, including aortic and pulmonary heart valve allografts. Since CryoLife’s inception in 1984, the company has processed over 18000 donated hearts, received from 150 Tissue Banks and Organ Procurement Organizations throughout the United States, and documented the implantation of more than 16000 cryopreserved allograft heart valves from 450 institutions in the United… CONTINUE READING

Topics from this paper.